共 32 条
[1]
Carmel AS(2012)The 25(OH)D level needed to maintain a favorable bisphosphonate response is >/=33 ng/ml Osteoporos Int 23 2479-2487
[2]
Shieh A(2012)25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis Bone 51 54-58
[3]
Bang H(2009)Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women Calcif Tissue Int 85 398-404
[4]
Bockman RS(2007)The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis BMC Musculoskelet Disord 8 3-1714
[5]
Peris P(2009)Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial J Rheumatol 36 1705-1013
[6]
Martinez-Ferrer A(2000)Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15 1006-1263
[7]
Monegal A(2009)Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial Lancet 373 1253-744
[8]
Martinez de Osaba MJ(2012)Clinical review: Do glucocorticosteroids alter vitamin D status? A systematic review with meta-analyses of observational studies J Clin Endocrinol Metab 97 738-1930
[9]
Muxi A(2011)Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab 96 1911-undefined
[10]
Guanabens N(undefined)undefined undefined undefined undefined-undefined